Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN14284 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 Mid IV Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Cohort 2 Mid SC Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Cohort 3 High IV Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Cohort 4 High SC Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Cohort 5 Higher IV Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Cohort 6 Highest IV Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Cohort 7 Low IV Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Cohort 8 Low SC Dose | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Name | Type | Description |
|---|---|---|
| REGN14284 | DRUG | Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol |
| Matching Placebo | DRUG | Single ascending IV or SC administration per the protocol |
Key Inclusion Criteria: 1. Has SARS-CoV-2-negative test result from a sample collected ≤72 hours prior to randomization as described in the protocol. 2. Has received complete primary series of standard-of-care COVID-19 vaccination per local guidance, completed at least 2 weeks prior to screening 3....
REGN14284 is an investigational small molecule developed by Regeneron Pharmaceuticals, Inc. (ticker: REGN). It is being studied as a COVID-19 therapeutic. The drug is in Phase 1 clinical development and has been evaluated in a single completed trial in healthy adult participants.
REGN14284 is made by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. Regeneron is the developer responsible for the clinical program evaluating this small molecule as a COVID-19 therapeutic.
REGN14284 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this drug.
REGN14284 has been studied in one clinical trial: NCT05505448, a Phase 1 trial titled "A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants." The trial was completed, enrolled 48 healthy adult participants in Belgium, and was randomized, double-blind, and controlled.
No, REGN14284 is not FDA approved. It is an investigational small molecule in Phase 1 clinical development. The only listed trial for REGN14284 has been completed, and no active trials are currently reported.